GE HealthCare and Mayo Clinic unveil GEMINI-RT: A bold research collaboration in radiation therapy and advanced cancer care

Key Terms

dosimetry medical

Dosimetry is the measurement and calculation of how much ionizing radiation is absorbed by people, tissues, or devices, similar to a thermostat tracking temperature in different rooms to know where and how much heat is present. Investors should care because accurate dosimetry underpins safety, treatment effectiveness, regulatory approval, and liability for products and services that use radiation—affecting market access, costs, and commercial risk.

predictive oncology medical

Predictive oncology uses biological data and computer models to forecast how a specific cancer will behave and how likely a patient is to respond to different treatments. For investors, it matters because these predictions can shrink drug-development costs, increase the chance of successful clinical trials, and create demand for tests or therapies that target patients most likely to benefit—similar to using a weather forecast to plan the best day for an outdoor event.

multi-modal therapies medical

Multi-modal therapies combine two or more different kinds of medical treatments—such as drugs, surgery, radiation, devices, or behavioral approaches—used together to treat a disease. For investors this matters because combining modes can improve outcomes and create stronger market demand, but it also raises development complexity, costs, regulatory hurdles and reimbursement questions, affecting timelines, risk and potential return much like a more elaborate product that can command a premium or require more investment to bring to market.

connected care medical

Connected care is a way of delivering healthcare that links patients, clinicians, devices and medical records through networks and apps so care can be coordinated remotely across locations and time. Think of it like a home thermostat that shares temperature, alerts and settings with a service center and your phone; for investors it matters because it can lower costs, expand service reach, create recurring revenue from platforms and devices, and change regulatory and reimbursement risks for healthcare companies.

biomarkers medical

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

theranostics medical

Theranostics combines a medical test with a targeted treatment so the same approach both finds disease and delivers therapy—like a guided missile that first locates a target then destroys it. For investors, it matters because pairing diagnosis and therapy can speed identification of patients who will benefit, reduce wasted treatments, create dual revenue streams (tests plus drugs), and alter regulatory and reimbursement dynamics that affect commercial potential.

AI-powered solutions technical

AI-powered solutions are software or systems that use machine learning and related artificial intelligence methods to analyze data, automate routine work, or make predictions and recommendations. For investors, they matter because they can lower costs, speed decision-making, and create new revenue opportunities much like a smart assistant or navigation system improves how a business runs; success can affect a company’s growth, margins, and competitive position.

• GE HealthCare and Mayo Clinic launch GEMINI-RT, a strategic initiative to personalize radiation therapy by integrating imaging, AI, and patient monitoring across the cancer care continuum.
• The collaboration focuses on four pillars, automation, predictive oncology, multi-modal therapies, and outpatient monitoring, with the aim to enhance clinical outcomes, reduce clinician burnout, and accelerate innovation in radiation oncology.

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) and Mayo Clinic today announced the GE HealthCare-Mayo Clinic Initiative in Radiation Therapy, known as GEMINI-RT, an ambitious new collaboration that aims to transform personalized radiation therapy and cancer care. Building on decades of collaboration and the original Strategic Radiology Research Collaboration signed in 2023, GEMINI-RT plans to drive innovation in prediction, planning, automation, workflow and monitoring for radiation oncology.

GEMINI-RT combines Mayo Clinic’s world-class clinical and research expertise with GE HealthCare’s leading technical and engineering innovation in oncology care and radiation therapy. The initiative aims to deliver comprehensive, personalized care by exploring integrating imaging, advanced therapies, dosimetry, and patient monitoring at every step of the patient journey—from detection and diagnosis to treatment and follow-up.

Radiation therapy is a cornerstone of cancer care, used in more than 50% of cases worldwide and for over 2 million U.S. patients annually^1,2. Rising global cancer incidence, 19.3 million new cases in 2022, continues to drive demand for this treatment³. Through GEMINI-RT, Mayo Clinic and GE HealthCare aim to make personalized radiation therapy accessible with new initiatives such as integrating streamlined, data-driven solutions, leveraging Mayo Clinic’s clinical expertise and patient outcomes data.

“GEMINI-RT is grounded in the concept of ‘twinning the patient, personalizing the beam’—a transformative approach made possible by Mayo Clinic’s extensive clinical expertise and outcomes data,” said Bryan Traughber, M.D., vice chair, innovation for radiation oncology, Mayo Clinic. “The combination of research and technological acumen could allow us to model individual patient journeys with precision, enabling radiation therapy treatments that are truly tailored to each patient.”

The collaboration will deepen efforts across four strategic areas:

• Automation: Collaborating on AI-powered solutions that can eliminate repetitive tasks and accelerate treatment planning
• Predictive Oncology: Harnessing clinical insights to personalize cancer treatment decisions and improve outcomes.
• Multi-modal Therapies: Exploring approaches that combine radiation with emerging treatments like targeted drugs and precision heating for more effective care.
• Connected Care: Using AI, biomarkers, and sensors to monitor patients beyond the clinic—with the aim to predict side effects early and support treatment at home.

“This effort enables us to collaborate on solutions that are not only leading-edge but also clinically meaningful, helping shape the future of personalized radiation therapy. By integrating innovative technology and AI across the care continuum, we can improve clinician experience, support high-quality patient care, and help reduce burnout among care teams,” said Dr. Ben Newton, Global Head of Oncology, GE Healthcare.

GEMINI-RT Research and activities will be based at Mayo Clinic’s campus in Rochester, Minnesota, leveraging both organizations’ strengths in clinical practice, research, and product development. This research initiative builds on the 2023 strategic radiology research alliance in which GE HealthCare and Mayo Clinic are collaborating on projects in advanced Magnetic Resonance (MR) technologies and techniques, theranostics treatment for cancer, and diagnostic and interventional ultrasound.

About Mayo Clinic

Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

[1] International Agency for Research on Cancer (IARC). 2023. “Expanding Global Access to Radiotherapy.” IARC. https://www.iarc.who.int/reference/expanding-global-access-to-radiotherapy/.

[2] American Society for Radiation Oncology (ASTRO). 2020. “Geographic Access to Radiation Therapy in the United States.” ASTRO Press Kit. https://www.astro.org/ASTRO/media/ASTRO/News%20and%20Publications/Press%20Kits/PDFs/2020/AM20_PressSlidesMaroongroge203.pdf.

[3] World Health Organization (WHO). 2024. “Global Cancer Burden Growing Amidst Mounting Need for Services.” WHO News Release. https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20251203542689/en/

Mayo Clinic Media Contact:

Tom Millikin

Millikin.Thomas@mayo.edu

GE HealthCare Media Contact:

Caitlin Lamey

+1 951 249 1401

caitlin.lamey@gehealthcare.com

Source: GE HealthCare